Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharma company, is scheduled to present additional data from its phase I imaging and dosimetry clinical trial of imaging agent MNPR-101-Zr at the upcoming European Association of Nuclear Medicine 2024 Annual Congress to be held in Hamburg, Germany on October 19-23, 2024.
MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, the company's proprietary first-in-class humanized monoclonal antibody. MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is expressed in numerous tumor types including pancreatic, breast, colorectal, and bladder.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com